Pang et al. used anti-MSLN CAR-T cells coexpressing human IL-7 and CCL19 (7 × 19 CAR-T cells) to initiate a phase I clinical trial in patients with advanced PC who were highly expressing MSLN. This evidence concerns the gene CCL19 and pachyonychia congenita.